Theralink Technologies Inc (EM) (THER)

Big Al and Faith never even let their THER shareholders know what was happening and instead allowed their shareholders to go to zero.

>>With BACK already in possession of such assets of Theralink, and a merger with Theralink no longer necessary to acquire such assets, on May 6, 2024, BACK, IMAC Merger Sub, Inc. (“Merger Sub”) and Theralink entered into a Termination Agreement,

https://www.globenewswire.com/en/news-release/2024/05/07/2876737/0/en/IMAC-Holdings-Acquires-Assets-of-Theralink-to-Continue-Precision-Medicine-Business.html

Well, it doesn't look like there's going to be any discussion here or learning. At least try to remember the posters here who pumped away at retails expense.

Signing off.
LC

Looks like it's a shell now. Big Al's specialty.

>>The reporting requirements are detailed in the Securities Exchange Act of 1934. They are extensive and can be burdensome for small publicly-listed firms. Some of these experience very little trading of their stock on the public exchange. Ownership may be dominated by a single family or by a small group of investors. For such circumstances, the benefits of being a public company may simply not be worth the time, money, and effort of preparing and filing periodic reports to the SEC.


>>As soon as the voluntary Form 15 is filed, the company is no longer required to make the principal filings required by the SEC. These include the annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K.

The real question is who gets to keep shareholders money?

WHY are they doing this?

But isn't it amazing that a company does not need to consult with their shareholders on such a move. Looks to be finished.

Hard to know without the CEO providing any input. Thanks Faith. It's already on the OTC so...Under 300 shareholders the filing might set up for a back-end merger. Or the merger is off and they just go dark for cost savings or both. The other possibility is they go private. This move appears to benefit that one large owner. They still need to report at least annually along with some other filings. But Faith should tell her few shareholders what's going on.

What does that mean for THER share holders?

Faith no more! Theralink going dark. Great work Faith, Mick and especially Big Al. That's quite a track record you've made for yourself. LOL

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Approximate number of holders of record as of the certification or notice date: 237.

Have faith??

Not good.

The new CEO lady is doin a bang up job!

>>On February 29, 2024, the Debentures became due and payable and the Company failed to pay the principal amount of the Debentures. As a result, an Event of Default occurred under Section 8(a)(i) of the Debentures. Upon the occurrence of an Event of Default, pursuant to Section 8(b) of the Debentures, the outstanding principal amount of the Debenture, plus accrued but unpaid interest, liquidated damages and other amounts owing in respect thereof through February 29, 2024, became, at the election of the holders of the Debentures, immediately due and payable in cash at a mandatory default amount of the sum of (a) 130% of the outstanding principal amount of the Debentures, plus (b) 130% of accrued and unpaid interest hereon, and (c) 130% of all other amounts, costs, expenses and liquidated damages due in respect of this Debentures. After February 29, 2024, the interest rate on the Debentures shall accrue at an interest rate equal to the lesser of 16% per annum or the maximum rate permitted under applicable law until the amounts due under the Debentures are fully paid. The current balance due under the Debentures is approximately $20.1 million.

Bring back the Mick! LOL

Should change symbol to YAWN.

How do you figure? My read is that all THER shares convert into .00013365…. shares of IMAC (BACK)

That’s what my math says, too

You will have THER shares plus IMAC shares.

LCJR

1,000,000 / 30 = 33,333 shares.
How are you doing the math?

LCJR

It would been so simple if they had just declared a market cap instead of all the crazy calculating and splits.

That is 1m THER is 133 after merger hope am wrong

This is not a good deal for me for every 1 share of THER I will get 0.0001336590 of #IMAC nah

New S4/A posted today:

https://www.otcmarkets.com/filing/html?id=17179108&guid=yjJ-keXhzjIqJth


LCJR

Looking good. Would explode if we got news on the merger.

LCJR

KEY REVERSAL DAY ALERT!

$THER - News Out!

https://www.otcmarkets.com/stock/THER/news/story?e&id=2720560


LCJR

0012. Getting closer to merger closing.

LCJR

.0009. A pure pump and dump.

Merger with $BACK happening any day now. Can’t wait!

LCJR

There goes the pump and dump.

Well, at this point I guess it doesn't make a difference, but getting their share structure right should've been done long ago.

"About to complete"

Why cap off the AS when they’re about to complete this merger with $BACK? Everything will change once that happens.

LCJR

Only? Currently they have practically an unlimited amount of authorized shares to dilute shareholders to hell. They need to cap that before anyone serious is going to hold this stock. What revenues?

That’s going to happen according to the filings the SEC is reviewing. However, even without that I’m not understanding your definition of a “retail trap.” The unrestricted share count is only 522,540,919. This is a real operating company with revenues about to close on a huge merger with another company currently listed on the Nasdaq exchange.

LCJR

Until they officially change the share structure this is a retail trap.

No doubt....but there are catalysts that could get a pop going. And that's all I'm looking for here....not looking to marry it.

Eye rolls. Nice pump and dump.

Loaded up....let's get this party started already!

$THER - we should hear something from the company this week regarding comments and responses to SEC. Merger and uplisting is on us, are you ready?

LCJR

Damn, did you really need to sell those 14s for a whopping $900 ?

LCJR

I saw that.

I posted earlier that I emailed them requesting a meeting and never heard from them. But right after I emailed them they put out that last PR. If they would respond I would gladly drive the 1 1/2 hour drive to meet with them.


LCJR

Thanks. I have no ability to PM here, but I’m
Interested if you visit their HQ.

That’s correct, but the uplifting to Nasdaq is also part of the merger. If they have everything approved by SEC, upon completion of merger, this could open up on Nasdaq with a PPS over $2

LCJR

So then, the Unrestricted stock available to trade will only be 17 million?? THERALINK will survive as a wholly-owned subsidiary of IMAC. So, we will still have THER shares, but reduced in number by 30x??

.002!!! I gotta get over there and take some pics or a video, Cancer is the key word here!

Hard pass? They will be listed on Nasdaq after that, which is also in the filings. At this price, you could buy a few mill and have enough after the RS to make awesome money. But to each his/her own.

LCJR

OS Unrestricted 522,540,919 11/13/2023
Outstanding Shares
6,151,499,919
11/13/2023
Restricted
5,628,959,000
11/13/2023

Filing states 30:1 reverse split coming. Not good. Hard pass on this one!

Krfg......also looks like it might have a nice run

Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4

Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (Nasdaq: BACK), announce that the companies have responded to the SEC’s first round of comments on the jointly filed form S-4. A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition. The Companies previously filed the S-4 on September 29th and received comments from the SEC in late October.

Theralink’s Chief Executive Officer, Faith Zaslavsky previously stated “The filing of the Form S-4 is a major milestone, as it signifies Theralink and IMAC have reached a definitive agreement and that the transaction is moving forward. The result of the Merger will be a well-positioned proteomics pure play squarely focused on the next generation of cancer care and protein analysis, an opportunity that all stakeholders in our companies are highly excited about. I am unaware of any other proteomics company with a robust patent estate, certified and accredited laboratory, and reimbursement agreements in place with major payors like Medicare that parallels what our new combined company possesses along with the leadership to execute and build value.”

The companies expect to hear back from the Securities and Exchange Commission within the next 10 business days.

About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink's technology targets multiple areas of oncology and drug development. In addition to the Company's first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Theralink Technologies, Inc. (OTC: THER) (“Theralink”) and IMAC Holdings, Inc. (Nasdaq: BACK) have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Theralink will merge with a newly formed, wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the “Merger”) in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.

Cautionary Note Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this communication that address activities, events or developments that IMAC or Theralink expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “potential,” “create,” “intend,” “could,” “would,” “may,” “plan,” “will,” “guidance,” “look,” “goal,” “future,” “build,” “focus,” “continue,” “strive,” “allow” or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the proposed Merger, the expected closing of the proposed Merger and the timing thereof and as adjusted descriptions of the post-transaction company and its operations, strategies and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, synergies, opportunities and anticipated future performance, including maintaining current Theralink management. Information adjusted for the proposed Merger should not be considered a forecast of future results. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. These include the risk that cost savings, synergies and growth from the proposed Merger may not be fully realized or may take longer to realize than expected; the possibility that shareholders of IMAC may not approve the issuance of new shares of IMAC common stock in the proposed Merger or that shareholders of IMAC may not approve the proposed Merger; the risk that a condition to closing of the proposed Merger may not be satisfied, that either party may terminate the Merger Agreement or that the closing of the proposed Merger might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed Merger; the occurrence of any other event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed Merger; the risk that changes in IMAC’s capital structure and governance could have adverse effects on the market value of its securities and its ability to access the capital markets; the ability of IMAC to retain its Nasdaq listing; the ability of Theralink to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on Theralink’s operating results and business generally; the risk the proposed Merger could distract management from ongoing business operations or cause IMAC and/or Theralink to incur substantial costs; the risk that Theralink may be unable to reduce expenses; the impact of the COVID-19 pandemic, any related economic downturn; the risk of changes in regulations effecting the healthcare industry; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond IMAC’s or Theralink’s control, including those detailed in IMAC’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on IMAC’s website at www.ir.imacregeneration.com and on the website of the Securities and Exchange Commission (the “SEC”) at www.sec.gov, and those detailed in Theralink’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on Theralink’s website at www.theralink.com and on the website of the SEC. All forward-looking statements are based on assumptions that IMAC and Theralink believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither IMAC nor Theralink undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Contact Information
Theralink Technologies, Inc.
Trevor McCartney
VP, Strategic Partnerships
Cell: (720) 800-2160
trevor.mccartney@theralink.com

https://www.globenewswire.com/newsroom/ti?nf=ODk3ODQ2MiM1OTI2MzI5IzUwMDExNzA4OA==
https://ml.globenewswire.com/media/NTkyMjViOTUtYjIwZi00NGIxLWI5ZjUtZGQwMzUyYzllZGFlLTUwMDExNzA4OA==/tiny/Theralink-Technologies-Inc-.png

Source: Theralink Technologies, Inc.

© 2023 GlobeNewswire, Inc.


https://www.otcmarkets.com/stock/THER/news/story?e&id=2689544


Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board

Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute (Inova) is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova’s Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients.

The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova’s molecular tumor board’s operational workflow. Over the past year, Inova has undertaken a feasibility study to develop and implement the procedures and infrastructure necessary for proteomic analysis within the context of the Inova Schar Molecular Tumor Board. The Theralink assay provides a direct means of determining the actionability of genomic derangements identified, as well as directly measuring the activation/elevation of protein drug targets otherwise missed by genomic analysis alone. Thus, the incorporation of key phosphoprotein and protein data generated by Theralink’s RPPA technology into the Inova MTB could synergize with current genomics analysis to produce more accurate treatment selection and patient-tailored therapy regimes.

Interim results of this pan-tumor study were presented at the 2023 ASCO Conference in Chicago. Specifically, the analysis examined the feasibility of incorporating laser capture microdissection (LCM) enrichment of tumor specimens and reverse phase protein array (RPPA) analysis with next generation sequencing (NGS) into a molecular tumor board for improving selection of targeted cancer therapy. Integrated review of the RPPA and NGS data by the MTB supported a clinical recommendation change for over half of the patients overall. Further, the proteomics data from the Theralink assay provided additional treatment considerations for 59% of the patients, the outcomes for whom continue to be monitored. Moreover, the collaboration with Inova and their MTB resulted in a recent finding1 wherein the Theralink proteomics data revealed a specific mechanism of resistance and likely lack of benefit to a targeted therapy being considered by the MTB for a patient with a rare form of inflammatory myofibroblastic cancer.

Lastly, Inova and Theralink presented the results of another important study at ASCO 2023 that focused on Theralink’s unique ability to quantitatively measure HER2 abundance and activation and found that nearly 50% of pancreatic tumor actually express moderate amounts of HER2 protein, which could be missed by existing commercial HER2 assays. While HER2 expression is not routinely evaluated in clinical practice for pancreatic cancer these results may have clinical implications, especially as new classes of HER2 antibody drug conjugates are considered for patients with HER2 non amplified tumors across organ sites.

“Theralink is extremely encouraged by the work done to date at Inova Schar Cancer Institute- the interim results and clinical intelligence speak for themselves. We look forward to completing this study with Inova for our mutual goal of improving outcomes for all cancer patients”, said Faith Zaslavsky, President and Chief Executive Officer of Theralink.

Dr. Timothy Cannon, who is the Sheridan Director of the Inova Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova said, “We have tested over 100 patients with Theralink’s RPPA technology as part of this study. We are hopeful final study analysis and results will continue to underscore the importance of real-time clinical integration of functional protein drug target activation data provided by the Theralink assay with NGS in the Inova MTB for cancer patients.”

Theralink and Inova will update findings and results post study completion. Published results are anticipated in early 2024.

About Theralink Technologies, Inc.

Theralink Technologies is a proteomics-based, precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink's technology targets multiple areas of oncology and drug development. In addition to the Company's first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Theralink Technologies, Inc. (OTC: THER) (“Theralink”) and IMAC Holdings, Inc. (Nasdaq: BACK) have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Theralink will merge with a newly formed, wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the “Merger”) in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.

Cautionary Note Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this communication that address activities, events or developments that IMAC or Theralink expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “potential,” “create,” “intend,” “could,” “would,” “may,” “plan,” “will,” “guidance,” “look,” “goal,” “future,” “build,” “focus,” “continue,” “strive,” “allow” or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the proposed Merger, the expected closing of the proposed Merger and the timing thereof and as adjusted descriptions of the post-transaction company and its operations, strategies and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, synergies, opportunities and anticipated future performance, including maintaining current Theralink management. Information adjusted for the proposed Merger should not be considered a forecast of future results. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. These include the risk that cost savings, synergies and growth from the proposed Merger may not be fully realized or may take longer to realize than expected; the possibility that shareholders of IMAC may not approve the issuance of new shares of IMAC common stock in the proposed Merger or that shareholders of IMAC may not approve the proposed Merger; the risk that a condition to closing of the proposed Merger may not be satisfied, that either party may terminate the Merger Agreement or that the closing of the proposed Merger might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed Merger; the occurrence of any other event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed Merger; the risk that changes in IMAC’s capital structure and governance could have adverse effects on the market value of its securities and its ability to access the capital markets; the ability of IMAC to retain its Nasdaq listing; the ability of Theralink to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on Theralink’s operating results and business generally; the risk the proposed Merger could distract management from ongoing business operations or cause IMAC and/or Theralink to incur substantial costs; the risk that Theralink may be unable to reduce expenses; the impact of the COVID-19 pandemic, any related economic downturn; the risk of changes in regulations effecting the healthcare industry; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond IMAC’s or Theralink’s control, including those detailed in IMAC’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on IMAC’s website at www.ir.imacregeneration.com and on the website of the Securities and Exchange Commission (the “SEC”) at www.sec.gov, and those detailed in Theralink’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on Theralink’s website at www.theralink.com and on the website of the SEC. All forward-looking statements are based on assumptions that IMAC and Theralink believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither IMAC nor Theralink undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

1 Hunt AL, et al. Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer. Oncologist. 2023 Aug 3;28(8):730-736.

Contact Information
Theralink Technologies, Inc.
Trevor McCartney
VP, Strategic Partnerships
Cell: (720) 800-2160
trevor.mccartney@theralink.com

https://www.globenewswire.com/newsroom/ti?nf=ODk3MjA1MyM1OTA4NDM2IzUwMDExNzA4OA==
https://ml.globenewswire.com/media/NGUwYjI5N2YtZmNkMi00NjZlLTg5ZjQtZWY5NzA3YmQ1NzBiLTUwMDExNzA4OA==/tiny/Theralink-Technologies-Inc-.png

Source: Theralink Technologies, Inc.

© 2023 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/THER/news/story?e&id=2678926

Note from Chartmaster: Chart shows now rising 50 day MA so trend is now higher!